scm logo

SCM Life Science (SCM Life Science, KOSDAQ 298060, CEO Lee Byung-gun), a company specializing in cell therapy, announced on the 24^th  that it has been elected as the target of a global IP (intellectual property) star company program organized by Incheon City and the Korean Intellectual Property Office. 

The Global IP Star Enterprise Promotion Project is that comprehensively supports intellectual property rights for three years by carefully selecting promising small and medium-sized enterprises with excellent export potential and technology in the region. In addition to global IP star company certification, the selected companies will receive intensive support for knowledge rights such as consulting with a total of 150 million won for 3 years, 50 million each year.

Specifically, it will receive support and consultation such as ▲ overseas application, OA, registration cost support ▲ patent technology promotion video production ▲ patent map ▲ design map, ▲ brand development ▲ non-English-speaking brand development ▲ corporate IP management diagnosis.

SCM Life Science seems to have been selected as a global IP star company in recognition of its differentiated technology and innovation in the field of cell therapy. The company is currently developing stem cell treatments for atopic dermatitis (clinical phase 2), chronic GVHD (clinical phase 2a), and acute pancreatitis (clinical phase 2a), and expanding its business to immunotherapy and Utah University and Cellsheet in the U.S.